Business Context and Reporting Period
Company: ImmuCell Corp.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1997
Business Overview: ImmuCell is a biotechnology company focused on developing diagnostic reagents, nutritional milk proteins (such as lactoferrin), and water testing technologies. The company operates with a strategy of demonstrating efficacy in clinical trials to secure corporate partners for funding and marketing rights.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Total Revenues | $1,300,240 | $1,416,011 |
| Net Profit (Loss) | $152,485 | $(11,678) |
| Net Profit Per Share | $0.06 | -- |
| Cash and Cash Equivalents | $1,061,287 | $1,143,309 |
| Net Cash from Operating Activities | $102,473 | $(216,623) |
| Total Assets | $3,188,683 | -- |
| Total Liabilities | $1,153,141 | -- |
| Stockholders' Equity | $2,035,542 | -- |
| Long-Term Debt | $508,800 | -- |
| Gross Margin (Product Sales) | 56% | 57% |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net profit of $152,485 in Q1 1997, reversing a net loss of $11,678 in the same period in 1996.
- Revenue Decline: Total revenues decreased by approximately 8% ($115,771) year-over-year. This was driven by a 39% drop in collaborative research and grant income, partially offset by a licensing fee of $75,000.
- Product Sales: Product sales decreased by 5% ($57,641) to $1.21 million, primarily due to lower sales of diagnostic reagents. However, sales of core products (First Defense and KamarHeatmount Detector) increased by 7%.
- Expense Reduction: Research and development (R&D) expenses plummeted by 59% ($295,056) to $206,002. This significant reduction was the primary driver of the net profit, as the company did not incur significant clinical trial costs in Q1 1997 that were present in Q1 1996.
- Liquidity: Net working capital increased by $85,000 to $1.49 million. Cash flow from operations turned positive, providing $102,473 compared to a usage of $216,623 in the prior year.
Outlook, Risks, and Management Commentary
- Future Losses Expected: Management explicitly states that to aggressively develop new products, the company expects to incur operating losses in the future.
- Capital Resources: The company believes it has sufficient capital to meet working capital requirements and finance operations for the next twelve months.
- Grant Funding: The company holds a $100,000 Phase I Small Business Innovation Research grant. As of April 1, 1997, approximately $32,000 remained available to fund development services for a Cryptosporidium water test.
- Debt Obligations: The company has significant debt obligations totaling approximately $744,000 (including current portion). Principal payments due subsequent to March 31, 1997, are approximately $174,000 in 1997, $230,000 in 1998, $104,000 in 1999, and $236,000 in 2000.
- Strategy: The strategy remains focused on Phase I/II clinical trials to attract corporate partners for funding and marketing rights.
Investor Verification Checklist
- Sustainability of Profit: Verify if the Q1 1997 profit is sustainable or if it is an anomaly caused by the temporary absence of clinical trial costs.
- Debt Servicing: Confirm the company's ability to meet the $174,000 in principal debt payments due in the remainder of 1997 given the expectation of future operating losses.
- Grant Utilization: Monitor the utilization of the remaining $32,000 in the SBIR grant and the status of the Cryptosporidium water test development.
- Revenue Concentration: Assess the risk associated with the decline in grant income and the heavy reliance (94%) on two specific products for sales revenue.
- Cash Burn Rate: Analyze the cash flow statement to ensure operating cash generation can cover capital expenditures and debt service without immediate equity dilution.